$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of side effects and contraindications of Adalimumab
2026-02-01 22:25:32
Check Details
The most common serious side effects of Tislelizumab treatment
2026-02-01 22:25:32
Check Details
What diseases is Ustekinumab mainly used to treat?
2026-02-01 22:25:32
Check Details
Is there a risk of relapse after discontinuation of Tarlatamab?
2026-02-01 22:25:32
Check Details
What are the known side effects of Elafibranor to be aware of?
2026-02-01 22:25:32
Check Details
Pharmacological mechanism and action characteristics of Thiotepa anti-tumor drug
2026-02-01 22:25:32
Check Details
Comparative analysis of the differences between Donanemab and Lencanezumab
2026-02-01 22:25:32
Check Details
How effective is Vorasidenib in treating IDH-mutant brain tumors?
2026-02-01 22:25:32
Check Details
How long does it usually take to take Seladelpar to see results?
2026-02-01 22:25:32
Check Details
Is there any adjustment to the latest price of Lazertinib in 2025?
2026-02-01 22:25:32
Check Details
Description of common injection sites and injection techniques for Bortezomib
2026-02-01 22:25:32
Check Details
Is it necessary to use Adalimumab for life after treatment?
2026-02-01 22:25:32
Check Details
1
2
...
1707
1708
1709
1710
1711
1712
1713
...
10226
10227
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
First CELMoD Drug Zenbexus Wins FDA Accelerated Approval for Multiple Myeloma
2
Elamipretide Side Effects and Medication Safety Guide: Injection Site Reactions and Storage Essentials
3
Dutasteride Soft Capsules: Comprehensive Side Effect Profile and Management Strategies
4
Oral Semaglutide Tablets: A Complete Guide to the GLP-1 Receptor Agonist for Type 2 Diabetes and Cardiovascular Protection
5
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
6
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
7
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
8
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
9
Asciminib (SCEMBLIX): STAMP Inhibitor Dosing Guide and Nomenclature Clarification for CML
10
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
11
Cabergoline Medication Guide: Contraindications, Treatment Costs, and Safety Monitoring Essentials
12
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment